Polymorphic compounds and uses thereof
The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
1. A solid form of Compound A:
wherein said solid form has one or more peaks in its XRPD selected from those at about 8.0 and about 13.1 degrees 2-theta.
2. The solid form according to claim 1 , wherein said solid form is a crystalline solid substantially free of amorphous Compound A.
3. The solid form according to claim 1 , wherein said solid form is substantially free of impurities.
4. The solid form according to claim 1 , having two peaks in its XRPD selected from those at about 8.0 and about 13.1 degrees 2-theta.
5. The solid form according to claim 1 , having an XRPD substantially similar to that depicted in FIG. 1 .
6. A pharmaceutical composition comprising the solid form of claim 1 and a pharmaceutically acceptable carrier, excipient, or adjuvant.
7. A solid form of Compound A:
wherein said solid form has one or more peaks in its XRPD selected from those at about 9.5, about 10.5, and about 13.8 degrees 2-theta.
8. The solid form according to claim 7 , having at least two peaks in its XRPD selected from those at about 9.5, about 10.5, and about 13.8 degrees 2-theta.
9. The solid form according to claim 7 , having an XRPD substantially similar to that depicted in FIG. 10 .
10. The solid form according to claim 7 , wherein said solid form is a crystalline solid substantially free of amorphous Compound A.
11. The solid form according to claim 7 , wherein said solid form is substantially free of impurities.
12. The solid form according to claim 7 , having peaks in its XRPD at about 9.5, about 10.5, and about 13.8 degrees 2-theta.
13. A pharmaceutical composition comprising the solid form of claim 7 and a pharmaceutically acceptable carrier, excipient, or adjuvant.